Proteomic analysis of butyrate effects and loss of butyrate sensitivity in HT29 colorectal cancer cells

Journal of Proteome Research

Volumn 8, Issue 3, 2009, Pages 1220-1227

  Fung, Kim Y C ^a   Lewanowitsch, Tanya ^a   Henderson, Steven T ^a   Priebe, Ilka ^a   Hoffmann, Peter ^b   McColl, Shaun R ^b   Lockett, Trevor ^a   Head, Richard ^a   Cosgrove, Leah J ^a  

^a CSIRO   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Butyrate; Butyrate insensitive; Colorectal cancer; Proteomics

Indexed keywords

ACTIN; BUTYRIC ACID; CORTACTIN; CYTOSKELETON PROTEIN; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; PEROXIREDOXIN 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL STRAIN HT29; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEOMICS;

APOPTOSIS; BUTYRATES; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HT29 CELLS; HUMANS; PROTECTIVE AGENTS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 65249159062     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr8009929     Document Type: Article

References (41)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57 (1), 43-66.
2. Topping, D. L.; Clifton, P. M. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysac-charides. Physiol. Rev. 2001, 81 (3), 1031-64.
3. Olmo, N.; Turnay, J.; Perez-Ramos, P.; Lecona, E.; Barrasa, J. I.; Lopez de Silanes, I.; Lizarbe, M. A. In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells. Toxicol. In Vitro 2007, 21 (2), 262-270.
4. Williams, E. A.; Coxhead, J. M.; Mathers, J. C. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc. Nutr. Soc. 2003, 62 (1), 107-15.
5. Della Ragione, F.; Criniti, V.; Della Pietra, V.; Borriello, A.; Oliva, A.; Indaco, S.; Yamamoto, T.; Zappia, V. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett. 2001, 499 (3), 199-204.
6. Daly, K.; Shirazi-Beechey, S. P. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol. 2006, 25 (1), 49-62.
7. Iacomino, G.; Tecce, M. F.; Grimaldi, C.; Tosto, M.; Russo, G. L. Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem. Biophys. Res. Commun. 2001, 285 (5), 1280-9.
8. Mariadason, J. M.; Arango, D.; Corner, G. A.; Aranes, M. J.; Hotchkiss, K. A.; Yang, W.; Augenlicht, L. H. A gene expression profile that defines colon cell maturation in vitro. Cancer Res. 2002, 62 (16), 4791-804.
9. Tan, H. T.; Zubaidah, R. M.; Tan, S.; Hooi, S. C.; Chung, M. C. 2-D DIGE analysis of butyrate-treated HCT-116 cells after enrichment with heparin affinity chromatography. J. Proteome Res. 2006, 5 (5), 1098-106.
10. Tan, S.; Seow, T. K.; Liang, R. C.; Koh, S.; Lee, C. P.; Chung, M. C.; Hooi, S. C. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int. J. Cancer 2002, 98 (4), 523-31.
11. Lopez de Silanes, I.; Olmo, N.; Turnay, J.; Gonzalez de Buitrago, G.; Perez-Ramos, P.; Guzman-Aranguez, A.; Garcia-Diez, M.; Lecona, E.; Gorospe, M.; Lizarbe, M. A. Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells. Cancer Res. 2004, 64 (13), 4593-600.
12. Ho, S. B.; Yan, P. S.; Dahiya, R.; Neuschwander-Tetri, B. A.; Basbaum, C.; Kim, Y. S. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. J. Cell Physiol. 1994, 160 (2), 213-26.
13. Olmo, N.; Turnay, J.; Lecona, E.; Garcia-Diez, M.; Llorente, B.; Santiago-Gomez, A.; Lizarbe, M. A. Acquisition of resistance to butyrate induces resistance to luminal components and other types of stress in human colon adenocarcinoma cells. Toxicol. In Vitro 2007, 21 (2), 254-61.
14. Fogh, J.; Fogh, J. M.; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 1977, 59 (1), 221-6.
15. Augeron, C.; Laboisse, C. L. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res. 1984, 44 (9), 3961-9.
16. Chalkley, R.; Shires, A. The isolation of HTC variant cells which can replicate in butyrate. Changes in histone acetylation and tyrosine aminotransferase induction. J. Biol. Chem. 1985, 260 (12), 7698-704.
17. Kucerova, D.; Stokrova, J.; Korb, J.; Sloncova, E.; Tuhackova, Z.; Sovova, V. Response of HT29 cells to butyrate depends on time of exposure and glucose deprivation. Int. J. Mol. Med. 2002, 10 (6), 779-84.
18. Ayllon, V.; Martinez, A. C.; Garcia, A.; Cayla, X.; Rebollo, A. Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis. EMBO J. 2000, 19 (10), 2237-46.
19. Berndt, N.; Dohadwala, M.; Liu, C. W. Constitutivelyactive protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr. Biol. 1997, 7 (6), 375-86.
20. Vasiliev, J. M. Cytoskeletal mechanisms responsible for invasive migration of neoplastic cells. Int. J. Dev. Biol. 2004, 48 (5-6), 425-39.
21. Yamazaki, D.; Kurisu, S.; Takenawa, T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005, 96 (7), 379-86.
22. Verma, A.; Mehta, K. Tissue transglutaminase-mediated chemore-sistance in cancer cells. Drug Resist. Updates 2007, 10 (4-5), 144-51.
23. Yonezawa, T.; Kobayashi, Y.; Obara, Y. Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line. Cell. Signalling 2007, 19 (1), 185-93.
24. Yin, L.; Laevsky, G.; Giardina, C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 2001, 276 (48), 44641-6.
25. Drexler, H. C.; Euler, M. Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. Apoptosis 2005, 10 (4), 743-58.
26. Mandal, M.; Vadlamudi, R.; Nguyen, D.; Wang, R. A.; Costa, L.; Bagheri-Yarmand, R.; Mendelsohn, J.; Kumar, R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem. 2001, 276 (13), 9699-704.
27. Ostrowski, J.; Bomsztyk, K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br. J. Cancer 2003, 89 (8), 1493-501.
28. Yamamoto, S.; Tomita, Y.; Hoshida, Y.; Sakon, M.; Kameyama, M.; Imaoka, S.; Sekimoto, M.; Nakamori, S.; Monden, M.; Aozasa, K. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin. Cancer Res. 2004, 10 (2), 651-7.
29. Park, J. E.; Lee, D. H.; Lee, J. A.; Park, S. G.; Kim, N. S.; Park, B. C.; Cho, S. Annexin A3 is a potential angiogenic mediator. Biochem. Biophys. Res. Commun. 2005, 337 (4), 1283-7.
30. Luo, C.; Pan, H.; Mines, M.; Watson, K.; Zhang, J.; Fan, G. H. CXCL12 induces tyrosine phosphorylation of cortactin, which plays a role in CXC chemokine receptor 4-mediated extracellular signal-regulated kinase activation and chemotaxis. J. Biol. Chem. 2006, 281 (40), 30081-93.
31. Buday, L.; Downward, J. Roles of cortactin in tumor pathogenesis. Biochim. Biophys. Acta 2007, 1775 (2), 263-73.
32. Donepudi, M.; Resh, M. D. c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell. Signalling 2008, 20 (7), 1359-67.
33. Timpson, P.; Lynch, D. K.; Schramek, D.; Walker, F.; Daly, R. J. Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res. 2005, 65 (8), 3273-80.
34. Madoz-Gurpide, J.; Lopez-Serra, P.; Martinez-Torrecuadrada, J. L.; Sanchez, L.; Lombardia, L.; Casal, J. I. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol. Cell. Proteomics 2006, 5 (8), 1471-83.
35. Warburg, O. On the origin of cancer cells. Science 1956, 123 (3191), 309-14.
36. Koukourakis, M. I.; Giatromanolaki, A.; Harris, A. L.; Sivridis, E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66 (2), 632-7.
37. Langbein, S.; Zerilli, M.; Zur Hausen, A.; Staiger, W.; Rensch-Boschert, K.; Lukan, N.; Popa, J.; Ternullo, M. P.; Steidler, A.; Weiss, C.; Grobholz, R.; Willeke, F.; Alken, P.; Stassi, G.; Schubert, P.; Coy, J. F. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br. J. Cancer 2006, 94 (4), 578-85.
38. Yeh, C. S.; Wang, J. Y.; Chung, F. Y.; Lee, S. C.; Huang, M. Y.; Kuo, C. W.; Yang, M. J.; Lin, S. R. Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. Oncol. Rep. 2008, 19 (1), 81-91.
39. Christofk, H. R.; Vander Heiden, M. G.; Harris, M. H.; Ramanathan, A.; Gerszten, R. E.; Wei, R.; Fleming, M. D.; Schreiber, S. L.; Cantley, L. C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452 (7184), 230-3.
40. Christofk, H. R.; Vander Heiden, M. G.; Wu, N.; Asara, J. M.; Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452 (7184), 181-6.
41. Lu, H.; Forbes, R. A.; Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 2002, 277 (26), 23111-5.